We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?
- Authors
Macquart-Moulin, G; Viens, P; Palangié, T; Bouscary, M L; Delozier, T; Roché, H; Janvier, M; Fabbro, M; Moatti, J P
- Abstract
This study was designed to investigate the quality of life (QOL) of patients enrolled onto the High-Dose Chemotherapy for Breast Cancer Study Group trial (PEGASE 02), a French pilot multicenter trial of the treatment of inflammatory breast cancer (IBC) aimed at evaluating (1) toxicity and feasibility of sequential high-dose chemotherapy (HDC) with recombinant human granulocyte colony-stimulating factor (filgrastim) and stem-cell support and (2) response to HDC in terms of pathologic response and survival.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Vol 18, Issue 4, p754
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2000.18.4.754